Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Aptevo Therapeutics Inc. (APVO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Visitors trend2W10W9M
0.3165+0.0065 (+2.10%)
At close: 04:00PM EDT
0.3122 -0.00 (-1.36%)
After hours: 04:47PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
Previous Close0.3100
Open0.3250
Bid0.3123 x 1000
Ask0.3225 x 1300
Day's Range0.3105 - 0.3250
52 Week Range0.3000 - 7.2000
Volume78,652
Avg. Volume327,801
Market Cap3.647M
Beta (5Y Monthly)5.23
PE Ratio (TTM)N/A
EPS (TTM)-3.4900
Earnings DateNov 08, 2023 - Nov 13, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for APVO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Aptevo Therapeutics Inc.
    Analyst Report: AbbVie IncAbbVie, a research-based biopharmaceutical company, was spun off from Abbott Laboratories in January 2013. The company is based in suburban Chicago. The shares are a component of the S&P 500.
    Rating
    Fair Value
    Economic Moat
    7 days agoArgus Research
View more
  • ACCESSWIRE

    Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update

    Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results for the quarter ended June 30, 2023 and provided a business update, including duration of remission (DOR) data for its lead clinical candidate, APVO436.

  • Insider Monkey

    10 Oversold Value Stocks To Buy

    In this piece, we will take a look at ten oversold value stocks to buy. If you want to skip an introduction to value investing and oversold stocks, then take a look at 5 Oversold Value Stocks To Buy. Value investing has multiple benefits, particularly for patient investors. Understanding the complexities of a firm’s business […]

  • ACCESSWIRE

    Aptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public Offering

    / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical stage biotechnology company focused on developing novel immuno-oncology therapeutics, today announced the closing of its previously announced public offering of 2,221,550 shares of common stock at a purchase price of $0.62 per share, Pre-Funded Warrants to purchase up to an aggregate of 5,842,967 shares of common stock at a purchase price of $0.619 per Pre-Funded Warrant,

Advertisement
Advertisement